Aprogen’s Biosimilar Remicade To Hit Japan Next Year?
This article was originally published in PharmAsia News
Executive Summary
South Korea-based biotech firm Aprogen's biosimilar version of Remicade (Johnson & Johnson's infliximab) is set to complete a Phase III clinical study in Japan as early as this month. The company’s Japanese partner will then file for local regulatory approval immediately after completing the trial and aims to launch the product in the country in the latter half of next year.
You may also be interested in...
Binex, Tongfang Rework Deal Amid Strained Korea-China Ties
With Tongfang Kontafarma's cancelation of an equity investment, Binex appears to have become the first South Korean biologics firm to be hit by an increasingly strained relationship between South Korea and China. The two companies will instead establish a Chinese joint venture.
Biosimilar Bummer: FDA Postpones Celltrion Infliximab Advisory Committee
Pending information requests lead to delay of the March 17 meeting.
AI Healthcare, Medical Devices Shine In Korea Q1 Financings
After the financing draught suffered by Korean bioventures in 2023, it now seems the VC market is poised for a recovery as investors shift attention again to the healthcare sector, with a spotlight on AI-based solutions and device firms.